Abivax launches $600M US share offering on Nasdaq
What's the deal? French biotech AbivaxDealroom has a profile for this one. Try Dealroom → has launched a public offering of American Depositary Shares (ADS) in the US, worth roughly $600 million.
Each ADS represents one ordinary share, trading on the Nasdaq under the symbol "ABVX." The final price and number of shares will be set through an accelerated book-building process.
Why now? Abivax wants to fund the US commercialisation of obefazimod, its lead drug candidate, plus further clinical research.
Trading of its ordinary shares on Euronext will be suspended on July 1, 2026, to align with the Nasdaq opening.
What could go wrong? With terms still to be set by book-building, the final price and share count remain uncertain. The offering's success hinges on investor appetite for a biotech betting heavily on a single lead drug.
The signal: Abivax is a late-stage biotech, and the move to suspend its Euronext trading and pivot to Nasdaq marks a decisive bet on US capital markets to bankroll the commercialisation push for obefazimod — the kind of leap European companies increasingly make when the deeper investor pools and richer valuations sit across the Atlantic.
Read more: Web Disclosure
Image credit: Generated with Gemini
